Regardless of the sequential decrease in Current Liabilities, during the third quarter 2026, Quick Ratio deteriorated to 12.62 above company average Quick Ratio.

Within Major Pharmaceutical Preparations industry 35 other companies have achieved higher Quick Ratio than Rhythm Pharmaceuticals Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 171, from total ranking in the second quarter 2026 at 793.

Explain Quick Ratio?
How much Cash & cash equivalents RYTM�s has?
What are RYTM�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/RYTM/financial-strength

https://api.csimarket.com/api/v1/companies/RYTM/fundamentals

https://api.csimarket.com/api/v1/companies/RYTM/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

RYTM Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-75.46 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-22.86 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	12.62	Subscribe	Subscribe	Subscribe	Subscribe
RYTM's Total Ranking	# 171	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-11.88 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-46.17 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 36
Healthcare Sector	# 52
Overall Market	# 171

Quick Ratio Statistics
High	Average	Low
62.36	12.26	2.26
(Sep 30 2018)		(Jun 30 2025)

Financial Statements
Rhythm Pharmaceuticals Inc 's Current Liabilities	$ 25 Millions	Visit RYTM's Balance sheet
Rhythm Pharmaceuticals Inc 's Cash & cash equivalent	$ 321 Millions	Visit RYTM's Balance sheet
Source of RYTM's Sales		Visit RYTM's Sales by Geography

Cumulative Rhythm Pharmaceuticals Inc 's Quick Ratio

RYTM's Quick Ratio for the trailling 12 Months

RYTM Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-40.83 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	22.69 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	6.05	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3722	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-22.33 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-5.46 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to RYTM Financial Strength Comparisons >> Go to Compare RYTM Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Rhythm Pharmaceuticals Inc 's average Cash & cash equivalent, this led to increase in in Rhythm Pharmaceuticals Inc 's Quick Ratio to 6.05, Quick Ratio remained below RYTM average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 425 other companies have achieved higher Quick Ratio than Rhythm Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2817 to 3722.

Explain Quick Ratio?
How much Cash & cash equivalents RYTM�s has?
What are RYTM�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 426
Healthcare Sector	# 868
Within the Market	# 3722

trailing twelve months Quick Ratio Statistics
High	Average	Low
44.89	11.91	2.69
(Dec 31 2018)		(Jun 30 2025)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Boundless Bio Inc	33.60	$ 62.894 Millions	$ 1.872 Millions
Avalyn Pharma Inc	32.64	$ 422.814 Millions	$ 12.955 Millions
Immix Biopharma Inc	30.89	$ 336.303 Millions	$ 10.889 Millions
Minerva Neurosciences Inc	30.46	$ 76.945 Millions	$ 2.526 Millions
Contineum Therapeutics Inc	30.45	$ 244.484 Millions	$ 8.028 Millions
Latigo Biotherapeutics, Inc.	28.73	$ 401.241 Millions	$ 13.964 Millions
Amylyx Pharmaceuticals Inc	26.44	$ 768.132 Millions	$ 29.048 Millions
Climb Bio Inc	25.98	$ 205.423 Millions	$ 7.906 Millions
Prothena Corporation Public Limited Company	23.73	$ 271.368 Millions	$ 11.434 Millions
Innoviva Inc	22.67	$ 1,134.297 Millions	$ 50.030 Millions
Kailera Therapeutics Inc	21.40	$ 901.454 Millions	$ 42.116 Millions
Cryoport inc	20.47	$ 653.343 Millions	$ 31.911 Millions
Roivant Sciences Ltd	20.30	$ 5,683.045 Millions	$ 279.911 Millions
Disc Medicine Inc	19.87	$ 682.816 Millions	$ 34.360 Millions
Relmada Therapeutics Inc	19.30	$ 202.123 Millions	$ 10.474 Millions
Mbx Biosciences Inc	19.14	$ 481.594 Millions	$ 25.167 Millions
Telomir Pharmaceuticals Inc	19.07	$ 4.516 Millions	$ 0.237 Millions
Equillium Inc	18.92	$ 53.322 Millions	$ 2.819 Millions
Onkure Therapeutics Inc	18.58	$ 163.305 Millions	$ 8.789 Millions
Alto Neuroscience Inc	17.90	$ 319.344 Millions	$ 17.836 Millions
Monopar Therapeutics Inc	17.65	$ 52.634 Millions	$ 2.982 Millions
Upstream Bio Inc	17.34	$ 207.365 Millions	$ 11.960 Millions
Siga Technologies Inc	17.27	$ 116.380 Millions	$ 6.738 Millions
Arrivent Biopharma inc	16.86	$ 393.691 Millions	$ 23.357 Millions
Keros Therapeutics Inc	16.36	$ 259.464 Millions	$ 15.858 Millions
Design Therapeutics Inc	16.36	$ 208.608 Millions	$ 12.753 Millions
Whitehawk Therapeutics Inc	16.25	$ 169.672 Millions	$ 10.441 Millions
Palvella Therapeutics Inc	15.85	$ 236.680 Millions	$ 14.928 Millions
Avalo Therapeutics Inc	15.63	$ 392.966 Millions	$ 25.135 Millions
Bioage Labs Inc	14.91	$ 283.637 Millions	$ 19.027 Millions

Date modified: 2026-11-04T15:25:17+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.